Delivery Order SPE2DB20D1047-SPE2DB25FF78Z
- Not listed
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $34,710.69. This firm fixed-price delivery order represents a non-set-aside competitive award and is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $13,364.72 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets in quantities of 30 units. This firm fixed price, competitively awarded contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) valued at $9,780.29 under a firm fixed-price contract type. The award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,172.92 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 20, 2025, with ultimate completion by August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $6,310.84 on August 5, 2025, for RINVOQ ER 30 MG tablets (30-count units). This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vehicle designated SPE2DX and extending through December 2026. The delivery order will be fulfilled from...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a delivery order valued at $22,851.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on July 18, 2025, with a completion date of July 21, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves no set-aside...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF78ZDelivery Order
The Defense Logistics Agency (DLA) awarded a $21,909.46 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 potential value through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal military and veteran healthcare procurement through the DLA Medical Supply Chain. The SPE2DX prime indefinite contract functions as a comprehensive global pharmaceutical support vehicle enabling the delivery of specialty medications, brand-name and generic drugs, vaccines, and related medical supplies to support military healthcare programs worldwide. This delivery order for RINVOQ ER—a medication used in the treatment of inflammatory conditions—exemplifies the company's ongoing role in fulfilling federal medical supply requirements across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.9k | 8/20/25 |